Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benjamin Reilly

Nurse Practitioner Hampton, VA Nurse Practitioner

NPI 1396265526 CMS profile 10576152

593 Aberdeen Rd, Hampton, VA 23661

Open in the dashboard

General payments

$1,645

91 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Reilly of Hampton, VA is reported in the CMS Open Payments database as having received $1,645 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $154 2
2023 General $31 1
2022 General $140 7
2021 General $1,319 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Reilly
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Benjamin Reilly were reported at $154. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Benjamin Reilly Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,319 $135 $40–$426 $132
2022 $140 $152 $48–$470 $149
2023 $31 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $154 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Actelion Pharmaceuticals US, Inc. $350 19 payments
  2. AstraZeneca Pharmaceuticals LP $214 13 payments
  3. Astellas Pharma US Inc $166 3 payments
  4. Novartis Pharmaceuticals Corporation $158 12 payments
  5. Smith+Nephew, Inc. $154 2 payments
  6. Janssen Pharmaceuticals, Inc $142 9 payments
  7. Pfizer Inc. $74 5 payments
  8. Amgen Inc. $71 4 payments
  9. Novo Nordisk Inc $54 3 payments
  10. E.R. Squibb & Sons, L.L.C. $47 3 payments
  11. Other $215 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,475 86 payments
  2. Education $170 5 payments
Products named General payments · program years 2021–2025
  1. OPSUMIT $350 19 payments
  2. ENTRESTO $158 12 payments
  3. REAL INTELLIGENCE $154 2 payments
  4. XARELTO $142 9 payments
  5. FARXIGA $130 8 payments
  6. ELIQUIS Cardiovascular;Metabolic Disease $74 5 payments
  7. VYNDAQEL $74 5 payments
  8. Repatha $71 4 payments
  9. Ozempic $54 3 payments
  10. ELIQUIS Cardiovascular $47 3 payments
  11. Other $369 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

654

Median for Nurse Practitioner: 389

Drug cost

$4,236

Median for Nurse Practitioner: $21,885

Branded share of claims

12.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 207 $1,746
Doxycycline Hyclate Generic 129 $861
Amoxicillin Generic 67 $307
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 28 $297
Cephalexin Generic 81 $277
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 32 $189
Methocarbamol Generic 19 $106
Azithromycin Generic 27 $101
Tobramycin Generic 14 $100
Cyclobenzaprine Hcl Generic 15 $94

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$70,260

Of which drugs: $412

Medicare patients

789

Average age 74

Services billed

1,520

460 women, 329 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 46%
Diabetes 21%
Ischemic heart disease 20%
Atrial fibrillation 18%
Depression 17%
Cancer 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record